---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-020882"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:46:32.407465+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics FY2023 net loss from operations down 50% to $17.1M; stenoparib complete response in Phase 2

## Summary
- Net loss from operations $17.1M in 2023 vs $34M in 2022 (down 50%); net loss $11.9M vs $16.1M.
- R&D expenses $7.1M and G&A $10.0M both flat year-over-year; no product revenue reported.
- Interim CEO Thomas Jensen appointed Dec 2023; former Eli Lilly exec Jeremy Graff named Executive Advisor.
- Dec 2023 Phase 2 stenoparib data: 1 complete response, 4 stable disease in evaluable advanced ovarian cancer patients.
- Expects interim Phase 2 stenoparib data in Q2 2024.

## SEC filing metadata
- accession: 0001213900-24-020882
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390024020882/0001213900-24-020882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390024020882/ea0201409-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-020882
- JSON: https://secwatch.observer/filing/0001213900-24-020882.json
- Plain text: https://secwatch.observer/filing/0001213900-24-020882.txt

## Key facts
- Earnings Releases
  Allarity Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $11.9 million.
  - Period: the year ended December 31, 2023
  - Net income: $11.9 million
  - Result: reported results
  source text: Net loss was $11.9 million for 2023, compared to $16.1 million for 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024020882/0001213900-24-020882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.